Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2015-04-20 |
Aduro Biotech (USA - CA) |
$124.3 million |
IPO |
|
|
IPO |
2015-04-17 |
Epizyme (USA - MA) |
$130.7 million |
IPO |
|
|
IPO |
2015-04-16 |
Autifony Therapeutics (UK) |
£3.3 million |
grant |
Biomedical Catalyst Fund (UK) Innovate UK (UK) Medical Research Council (UK) |
CNS diseases - Mental diseases |
Grant |
2015-04-16 |
Neurotrope BioScience (USA - NJ) |
|
|
FRAXA Research Foundation (USA - MA) |
Neurodegenerative diseases |
Grant |
2015-04-15 |
uniqure (The Netherlands) |
$82.4 million (€76.5 million) |
follow-on public offering |
|
Genetic diseases - Rare diseases |
Private placement |
2015-04-15 |
Myokardia (USA - CA) |
$46 million |
series B financing round |
Casdin Capital (USA - NY) Cormorant Asset Management (USA - MA) Perceptive Life Sciences (USA - NY) BridgeBio (USA - CA) Sanofi (France) |
Cardiovascular diseases |
Series B financing round |
2015-04-13 |
Angionetics, a newly-formed subsidiary of Taxus Cardium (USA - CA) |
$ 3 million |
equity investment |
Shenzhen Qianhai Taxus (China) |
Cardiovascular diseases |
Fundraising |
2015-04-09 |
Minoryx Therapeutics (Spain) |
€2.4 million |
financing round |
la Caixa (Spain) Sanfilippo Foundation Switzerland (Switzerland) Healthequity (Spain) |
Rare diseases |
Financing round |
2015-04-09 |
Antabio (France) |
€ 1 million |
subvention |
BpiFrance (France) |
Infectious diseases |
Subvention |
2015-04-09 |
Neostem (USA - NY) |
$1 million |
grant |
California Institute of Regenerative Medicine (CIRM) (USA - CA) |
Ophtalmalogical diseases - Genetic diseases - Rare diseases |
Grant |
2015-04-09 |
Asceneuron (Switzerland) |
$325,000 |
grant |
Alzheimer’s Drug Discovery Foundation (ADDF) (USA - NY) |
Neurodegenerative diseases |
Grant |
2015-04-08 |
Prothena (Ireland) |
|
capital increase |
|
|
Capital increase |
2015-04-07 |
Nabriva Therapeutics (Austria) |
$120 million |
series B financing round |
Vivo Capital (USA - CA) OrbiMed (USA - NY) EcoR1 Capital (USA - CA) Tavistock Life Sciences (USA - CA) HBM Phase4 Partners (UK) Wellcome Trust (UK) GLSV (Germany) Novartis Venture Fund (Switzerland) |
Infectious diseases |
Series B financing round |
2015-04-07 |
PhoreMost (UK) |
£2.5 million ($3.8 million) |
Financing round |
Jonathan Milner (UK) Amadeus Capital (UK) Sunil Shah and Prashant Shah (O2H Ventures) (UK) Cambridge Enterprise (UK) Dr Chris Torrance (UK) |
Technology - Services - Cancer - Oncology |
Financing round |
2015-04-06 |
Intercept Pharmaceuticals (USA - NY) |
$366.8 million |
financing round |
|
|
Financing round |
2015-04-06 |
Iteos Therapeutics (Belgium) ImaBiotech (France) |
€0.8 million |
grant |
Walloon Region (Belgium) Bpifrance (France) |
|
Grant |
2015-04-01 |
Tecrea (UK) Cobra Biologics (Sweden) |
£112,291 |
grant |
Innovate UK (UK) |
Technology - Services |
Grant |
2015-03-31 |
Atyr Pharma (USA - CA) |
$76 Million |
series E financing round |
Sofinnova Ventures (France) undisclosed large institutional investor in the biotechnology industry, Federated Investors (USA - PA), Deerfield (USA - NY), Rock Springs Capital Management (USA - MD) EcoR1 Capital (USA - CA), Sphera Global Healthcare (Israel - USA - NY), two additional undisclosed institutional investors |
Cancer - Oncology - Genetic diseases |
Financing round |
2015-03-31 |
Diamyd Medical (Sweden) |
SEK 15 million |
private placement |
undisclosed group of international institutional investors, previously not shareholders in Diamyd Medical |
Autoimmune diseases - Immunological diseases - Metabolic diseases |
Private placement |
2015-03-31 |
Tiziana Life Sciences (UK) |
£2.55 million (€3.48 million) |
private placement |
|
Cancer - Oncology |
Private placement |